Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Department of Defense (DoD) Defense Health Agency is seeking pharmaceutical manufacturers to submit pricing quotes for newly approved drugs to be considered for placement on the DoD Uniform Formulary (UF) through a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP). The solicitation covers seven newly approved drugs across various therapeutic classes, including neurological agents, oncological agents, antibiotics, antihemophilic factors, white blood cell stimulants, and insulin devices. Manufacturers must complete clinical questionnaires and submit detailed pricing information using specific templates, with a pre-quotation teleconference scheduled for January 8, 2025, and final quotes due by January 16, 2025, for review at the February 5-6, 2025 Pharmacy and Therapeutics (P&T) Committee meeting. The evaluation will focus on the relative clinical effectiveness and cost-effectiveness of pharmaceutical agents, with potential classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. Manufacturers must provide pricing for Military Treatment Facility, Mail Order, and TRICARE retail scenarios, including Federal Ceiling Prices and additional discount options.

The solicitation does not have a specific set-aside designation and covers pharmaceutical agents across multiple therapeutic classes to be evaluated for the TRICARE pharmacy benefits program. The place of performance is located in San Antonio, Texas, with the potential for nationwide distribution through military treatment facilities and the TRICARE pharmacy network. While specific award values are not explicitly stated, the solicitation provides pricing templates for up to 10 newly approved drugs across various package sizes and dispensing venues. The contract mechanism allows for Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements to be awarded based on the P&T Committee's recommendations. Manufacturers must be prepared to implement pricing within 14 days of contract signature and comply with prior authorization requirements and potential step therapy protocols. The solicitation is classified under the Pharmaceutical Preparation Manufacturing NAICS category (325412) and Drugs and Biologicals PSC category (6505), indicating a comprehensive approach to pharmaceutical procurement for the military healthcare system.